Dataset Information

Real-Time Quality Index to Control Data Loss in Real-Life Cardiac Monitoring Applications.

ABSTRACT: Wearable cardiac sensors pave the way for advanced cardiac monitoring applications based on heart rate variability (HRV). In real-life settings, heart rate (HR) measurements are subject to motion artifacts that may lead to frequent data loss (missing samples in the HR signal), especially for commercial devices based on photoplethysmography (PPG). The current study had two main goals: (i) to provide a white-box quality index that estimates the amount of missing samples in any piece of HR signal; and (ii) to quantify the impact of data loss on feature extraction in a PPG-based HR signal. This was done by comparing real-life recordings from commercial sensors featuring both PPG (Empatica E4) and ECG (Zephyr BioHarness 3). After an outlier rejection process, our quality index was used to isolate portions of ECG-based HR signals that could be used as benchmark, to validate the output of Empatica E4 at the signal level and at the feature level. Our results showed high accuracy in estimating the mean HR (median error: 3.2%), poor accuracy for short-term HRV features (e.g., median error: 64% for high-frequency power), and mild accuracy for longer-term HRV features (e.g., median error: 25% for low-frequency power). These levels of errors could be reduced by using our quality index to identify time windows with few or no data loss (median errors: 0.0%, 27%, and 6.4% respectively, when no sample was missing). This quality index should be useful in future work to extract reliable cardiac features in real-life measurements, or to conduct a field validation study on wearable cardiac sensors.

SUBMITTER: Vila G

PROVIDER: S-EPMC8400129 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ObjectiveContinuous glucose monitoring (CGM) is the standard of care for glucose monitoring in children with diabetes, however there are limited data reporting their use in hyperinsulinaemic hypoglycaemia (HH). Here, we evaluate CGM accuracy and its impact on quality of life in children with HH.MethodsReal-time CGM (Dexcom G5 and G6) was used in children with HH aged 0-16years. Data from self-monitoring capillary blood glucose (CBG) and CGM were collected over a period of up to 28days and analysed. Quality of life was assessed by the PedsQL4.0 general module and PedsQL2.0 family impact module, completed by children and their parents/carers before and after CGM insertion. Analysis of accuracy metrics included mean absolute relative difference (MARD) and proportion of CGM values within 15, 20, and 30% or 15, 20, and 30 mg/dL of reference glucose values >100 mg/dL or ≤100 mg/dL, respectively (% 15/15, % 20/20, % 30/30). Clinical reliability was assessed with Clarke error grid (CEG) analyses.ResultsProspective longitudinal study with data analysed from 40 children. The overall MARD between reference glucose and paired CGM values (n=4,928) was 13.0% (Dexcom G5 12.8%, Dexcom G6 13.1%). The proportion of readings meeting %15/15 and %20/20 were 77.3% and 86.4%, respectively, with CEG analysis demonstrating 97.4% of all values in zones A and B. Within the hypoglycaemia range (<70 mg/dL), the median ARD was 11.4% with a sensitivity and specificity of 64.2% and 91.3%, respectively. Overall PedsQL child report at baseline and endpoint were 57.6 (50.5 - 75.8) and 87.0 (82.9 - 91.2), and for parents were 60.3 (44.8 - 66.0) and 85.3 (83.7 - 91.3), respectively (both p<0.001).ConclusionUse of CGM for children with HH is feasible, with clinically acceptable accuracy, particularly in the hypoglycaemic range. Quality of life measures demonstrate significant improvement after CGM use. These data are important to explore use of CGM in disease indications, including neonatal and paediatric diabetes, cystic fibrosis and glycogen storage disorders.

Dataset Information

Real-Time Quality Index to Control Data Loss in Real-Life Cardiac Monitoring Applications.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets